Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Lymphocyte Subsets in Hemodialyzed HCV+ and HCV– Patients

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of our study was to get information on the immune status of patients who undergo haemodialysis in the presence of an HCV infection. This virus infects not only hepatocytes, but also blood mononuclear cells, in particular B cells [1], but we do not know the role of this lymphocyte involvement in the maintenance and progression of hepatitis. The impairment of the cell-mediated immune response in uraemic patients is well known, for example only 50–60% of uraemic patients undergo a seroconversion after HBV vaccine, compared to 95% of the normal population. Paradoxically the immunodeficiency is concomitant with an activation of related cells which is increased rather than ameliorated by the dialysis treatment [2]. In these patients lymphocytopenia is also present with a reduction of the absolute number of T lymphocytes which remain normal in percentage. The study was performed on the following groups of subjects.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1998
          February 1998
          26 January 1998
          : 78
          : 2
          : 226-227
          Affiliations
          a Istituto di Patologia Generale, Università di Perugia, b USL 1 Alto Tevere Umbro, Città di Castello, c Dipartimento di Biomedicina, Sezione di Virologia, Università di Pisa, Italy
          Article
          44918 Nephron 1998;78:226–227
          10.1159/000044918
          9496745
          © 1998 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Tables: 1, References: 4, Pages: 2
          Product
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/44918
          Categories
          Letter to the Editor

          Cardiovascular Medicine, Nephrology

          Comments

          Comment on this article